Agbalalah Tarimoboere, Bur Doofan, Nwonu Ezinne JaneFrances, Rowaiye Adekunle Babajide
Department of Anatomy, Faculty of Basic Medical Sciences, Baze University, Abuja, Nigeria.
Department of Medical Biotechnology, National Biotechnology Development Agency, Abuja, Nigeria.
Anemia. 2024 Mar 19;2024:5431000. doi: 10.1155/2024/5431000. eCollection 2024.
Sickle cell disease has witnessed a 41.4% surge from 2000 to 2021, significantly affecting morbidity and mortality rates, particularly in children from regions with elevated under-5 mortality rates. Gut microbiota dysbiosis is increasingly recognised in SCD, exacerbating complications, particularly chronic pain, marked by significant alterations of proinflammatory bacteria abundance. This review explores the therapeutic potential of and spp. in alleviating SCD-related complications, emphasising their roles in maintaining gut barrier integrity, reducing inflammation, and modulating immune responses.
A literature search up to November 2023 using PubMed, MEDLINE, and Google Scholar databases explored SCD pathophysiology, gut microbiota composition, spp. abundance, pain and gut dysbiosis in SCD, and butyrate therapy.
spp. supplementation shows promise in alleviating chronic pain by addressing gut dysbiosis, offering new avenues for sustainable SCD management. This approach holds the potential for reducing reliance on reactive treatments and improving overall quality of life. This research underscores the pivotal role of the gut microbiome in SCD, advocating for personalised treatment approaches.
Further exploration and clinical trials are needed to harness the full potential of these gut bacteria for individuals affected by this challenging condition.
从2000年到2021年，镰状细胞病激增了41.4%，显著影响发病率和死亡率，尤其是在五岁以下死亡率较高地区的儿童中。镰状细胞病患者肠道微生物群失调的情况日益受到关注，这加剧了并发症，尤其是慢性疼痛，其特征是促炎细菌丰度发生显著变化。本综述探讨了[具体菌种1]和[具体菌种2]在减轻镰状细胞病相关并发症方面的治疗潜力，强调它们在维持肠道屏障完整性、减轻炎症和调节免疫反应中的作用。
截至2023年11月，通过使用PubMed、MEDLINE和谷歌学术数据库进行文献检索，探讨镰状细胞病的病理生理学、肠道微生物群组成、[具体菌种1]丰度、镰状细胞病中的疼痛和肠道失调以及丁酸盐疗法。
补充[具体菌种1]有望通过解决肠道失调来减轻慢性疼痛，为镰状细胞病的可持续管理提供新途径。这种方法有可能减少对反应性治疗的依赖并改善整体生活质量。这项研究强调了肠道微生物群在镰状细胞病中的关键作用，提倡采用个性化治疗方法。
需要进一步探索和开展临床试验，以充分发挥这些肠道细菌对受这种具有挑战性疾病影响的个体的潜力。
